89bio Inc (ETNB)
7.93
-0.82
(-9.37%)
USD |
NASDAQ |
Nov 15, 16:00
8.31
+0.38
(+4.79%)
After-Hours: 20:00
89bio Research and Development Expense (TTM): 267.33M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 267.33M |
| June 30, 2024 | 157.30M |
| March 31, 2024 | 147.35M |
| December 31, 2023 | 122.23M |
| September 30, 2023 | 107.70M |
| June 30, 2023 | 98.48M |
| March 31, 2023 | 83.25M |
| December 31, 2022 | 80.80M |
| September 30, 2022 | 82.71M |
| June 30, 2022 | 84.10M |
| March 31, 2022 | 80.05M |
| Date | Value |
|---|---|
| December 31, 2021 | 70.33M |
| September 30, 2021 | 58.12M |
| June 30, 2021 | 45.74M |
| March 31, 2021 | 38.55M |
| December 31, 2020 | 36.20M |
| September 30, 2020 | 34.62M |
| June 30, 2020 | 30.09M |
| March 31, 2020 | 24.82M |
| December 31, 2019 | 21.35M |
| September 30, 2019 | 17.85M |
| June 30, 2019 | 14.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
21.35M
Minimum
Dec 2019
267.33M
Maximum
Sep 2024
83.56M
Average
80.42M
Median
Research and Development Expense (TTM) Benchmarks
| Madrigal Pharmaceuticals Inc | 281.71M |
| Eli Lilly and Co | 10.53B |
| Viking Therapeutics Inc | 91.16M |
| Akero Therapeutics Inc | 231.60M |
| NovaBay Pharmaceuticals Inc | 0.064M |